American Cancer Society reverses course, recommending routine PSA screening for prostate cancer

The American Cancer Society has updated its prostate cancer screening guidance to recommend routine PSA testing, reversing a position held since 2010 and reigniting debate about population-level screening strategy.

Published · AI-drafted summary based on 2 public sources
Illustration for oncology story
Illustrative image — not from the source article.
Share

The American Cancer Society (ACS) has issued updated guidance recommending routine PSA (prostate-specific antigen) screening for prostate cancer, marking a significant reversal of the organisation's position held since 2010. Two reports from STAT News published on 12 November 2026 — a news article and a secondary morning briefing item — cover the development.

The ACS's previous guidance, adopted in 2010, moved away from recommending routine population-level PSA screening owing to concerns about overdiagnosis and the harms associated with follow-up investigation and treatment of clinically insignificant disease. The new guidance, details of which were reported by STAT News but not fully reproduced in the feed lede, appears to focus on men aged 50 to 69. The reporting frames this as a reversal rather than an incremental amendment.

Prostate cancer screening policy has long been contested territory in oncology and primary care. Published guidance from bodies including the US Preventive Services Task Force has previously recommended shared decision-making rather than universal screening for average-risk men. The ACS update does not supersede national regulatory or guideline-body positions in other jurisdictions; UK guidance from NICE and NHS England remains independent of ACS recommendations.

Genetic factors — including pathogenic variants in BRCA2, BRCA1, ATM, and HOXB13, and polygenic risk scores — have an established role in hereditary prostate cancer risk assessment, though the ACS announcement as reported appears to address population-level PSA screening rather than hereditary risk pathways specifically. Genetic Current will update this summary when the full ACS guideline document is available.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source STAT News · 2026-11-12
    American Cancer Society revises guidelines, urges routine PSA screening for prostate cancer
  2. STAT News · 2026-11-12
    Experts update prostate cancer screening guidelines for men

Tags

prostate-cancer psa-screening cancer-screening guideline-update acs oncology cancer-policy
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List